Atria Wealth Solutions Inc. Sells 831 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Atria Wealth Solutions Inc. trimmed its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 32.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,716 shares of the medical research company’s stock after selling 831 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in IQVIA were worth $337,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Capital Performance Advisors LLP acquired a new position in shares of IQVIA in the 3rd quarter worth approximately $27,000. Synergy Asset Management LLC acquired a new position in shares of IQVIA in the 4th quarter worth approximately $33,000. Avior Wealth Management LLC lifted its position in shares of IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after purchasing an additional 87 shares during the period. Assetmark Inc. lifted its position in shares of IQVIA by 612.5% in the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after purchasing an additional 196 shares during the period. Finally, Ashton Thomas Securities LLC acquired a new position in shares of IQVIA in the 3rd quarter worth approximately $57,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insider Transactions at IQVIA

In other news, Director John G. Danhakl bought 1,275 shares of IQVIA stock in a transaction dated Tuesday, December 3rd. The stock was purchased at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the purchase, the director now directly owns 1,275 shares in the company, valued at $255,739.50. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.60% of the company’s stock.

IQVIA Stock Performance

IQV opened at $188.89 on Friday. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The company’s fifty day moving average price is $199.13 and its two-hundred day moving average price is $214.96. IQVIA Holdings Inc. has a 1-year low of $184.66 and a 1-year high of $261.73. The company has a market cap of $33.26 billion, a price-to-earnings ratio of 25.19, a PEG ratio of 1.99 and a beta of 1.48.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on IQV shares. UBS Group dropped their price target on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. JPMorgan Chase & Co. dropped their price target on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 18th. Bank of America dropped their target price on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. TD Cowen dropped their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Finally, Deutsche Bank Aktiengesellschaft dropped their target price on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Four investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $251.22.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.